1. A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation
- Author
-
Amanda Jia Qi Ooi, Chloe Wong, Timothy Wei Ern Tan, Trina Priscilla Ng, Yao Neng Teo, Yao Hao Teo, Nicholas L. Syn, Andie H. Djohan, Yinghao Lim, Leonard L. L. Yeo, Benjamin Y. Q. Tan, Mark Yan-Yee Chan, Kian-Keong Poh, William K. F. Kong, Ping Chai, Tiong-Cheng Yeo, James W. Yip, Ivandito Kuntjoro, and Ching-Hui Sia
- Subjects
Pharmacology ,Stroke ,Transcatheter Aortic Valve Replacement ,Treatment Outcome ,Fibrinolytic Agents ,Atrial Fibrillation ,Administration, Oral ,Anticoagulants ,Humans ,Pharmacology (medical) ,Hemorrhage ,General Medicine ,Brain Ischemia - Abstract
Transcatheter aortic valve replacement (TAVR) is increasingly carried out in patients with aortic valvular conditions. Atrial fibrillation (AF) is a common comorbidity among patients undergoing TAVR. Despite this, there remains a paucity of data and established guidelines regarding anticoagulation use post-TAVR in patients with AF.Four databases were searched from inception until 12 October 2021. A title and abstract sieve, full-text review and data extraction were conducted by independent authors, and articles including patients without AF were excluded. The Review Manager (Version 5.4) was utilised in data analysis.A total of 25,199 post-TAVR patients with AF were included from seven articles, with 9764 patients on non-vitamin K antagonist oral anticoagulants (NOAC) and 15,435 patients on vitamin K antagonists (VKA). In this analysis, there was a significantly lower risk of all-cause mortality at 1 year (RR: 0.75, CI: 0.58-0.97, p = 0.04, IWhile the results of this analysis reveal NOAC as a potential alternate treatment modality to VKA in post-TAVR patients with AF, further research is needed to determine the full safety and efficacy profile of NOAC (PROSPERO: CRD42021283548).
- Published
- 2022